(4-Chloro-2-methylphenyl)acetonitrile | 16470-10-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-Chloro-2-methylphenyl)acetonitrile
• 英文别名: 4-chloro-2-methylbenzyl cyanide；4-Chloro-o-tolylacetonitril；2-(4-Chloro-2-methylphenyl)acetonitrile
• CAS: 16470-10-3
• 化学式: C₉H₈ClN
• mdl: MFCD09923675
• 分子量: 165.622
• InChiKey: HVVQFXWATRLPQE-UHFFFAOYSA-N

物化性质

• 沸点：
  277.8±25.0 °C(Predicted)
• 密度：
  1.151±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (4-Chloro-2-methylphenyl)acetonitrile 在 sodium 、 一水合肼 、 溶剂黄146 、 N,N-二乙基苯胺 、 三氯氧磷 作用下， 以 溶剂黄146 、 甲苯 为溶剂， 生成 [3-(4-Chloro-2-methyl-phenyl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-(1-ethyl-propyl)-amine
  参考文献：
  名称：

  The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5- a ]-pyrimidine: A corticotropin-releasing factor (hCRF 1 ) antagonist

  摘要：

  Structure-activity relationship studies led to the discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine 11-31 (DMP904), whose pharmacological profile strongly supports the hypothesis that hCRF(1) antagonists may be potent anxiolytic drugs. Compound 11-31 (hCRF(1) K-i= 1.0 +/- 0.2 nM (n = 8)) was a potent antagonist of hCRF(1)-coupled adenylate cyclase activity in HEK293 cells (IC50 = 10.0 +/- 0.01 nM versus 10 nM r/hCRF, I? = 8); alpha-helical CRF(9-41) had weaker potency (IC50 = 286 +/- 63 nM, n = 3). Analogue 11-31 had good oral activity in the rat situational anxiety test; the minimum effective dose for 11-31 was 0.3 mg/kg (po). Maximal efficacy (approximately 57% reduction in latency lime in the dark compartment) was observed at this dose. Chlordiazepoxide caused a 72% reduction in latency at 20 mg/kg (po). The literature compound 1 (CP154526-1. 30 mg/kg (po)) was inactive in this lest. Compound 11-31 did not inhibit open-field locomotor activity at 10, 30, and 100 mg/kg (po) in rats. In beagle dogs, this compound (5 mg/kg, iv, po) afforded good plasma levels. The key iv pharmacokinetic parameters were t(1/2), CL and V-d.ss values equal to 46.4 +/- 7.6 h, 0.49 +/- 0.08 L/kg/h and 23.0 +/- 4.2 L/kg, respectively. After oral dosing. the mean C-max, T-max, t(1/2) and bioavailability values were equal to 1260 +/- 290 nM, 0.75 +/- 0.25 h, 45.1 +/- 10.2 h and 33.1%, respectively. The overall rat behavioral profile of this compound suggests that it may be an anxiolytic drug with a low motor side effect Liability. (C) 2000 DuPont Pharmaceuticals Company. Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00271-0
• 作为产物：
  描述：

  4-氯-2-甲基苯甲酸乙酯 在 吡啶 、 lithium aluminium tetrahydride 、 氯化亚砜 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 0.33h， 生成 (4-Chloro-2-methylphenyl)acetonitrile
  参考文献：
  名称：

  Esters of 2-phenylalkanenitriles and antifungal compositions containing them

  摘要：

  2-苯基烷基腈的酯，如3-乙氧基-2-(2-氯-5-(二氟甲氧基)苯基)丙腈和3-乙氧基-2-(4-氯苯基)丙腈，以及含有这些酯的组合物，在极低浓度下作为杀真菌剂是有用的。

  公开号：

  US20080153905A1

文献信息

• Substituted Pyrrolidine-2-Carboxamides
  申请人：Ding Qingjie

  公开号：US20100075948A1

  公开（公告）日：2010-03-25

  There are provided compounds of the formula wherein X, Y, R 1 , R 2 , R 3 , R 3 , R 4 , R 5 , R 6 and R 7 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

  提供了以下式的化合物 其中X、Y、R1、R2、R3、R3、R4、R5、R6和R7如本文所述，以及其对映体和药用可接受的盐和酯。这些化合物可用作抗癌药物。
• [EN] MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS<br/>[FR] MACROCYCLES À GROUPES HÉTÉROCYCLIQUES P2' SERVANT D'INHIBITEURS DU FACTEUR XIA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015116886A1

  公开（公告）日：2015-08-06

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽酶的双重抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• Esters of 2-phenylalkanenitriles and antifungal compositions containing them
  申请人：Stoutamire Donald Wesley

  公开号：US20080153905A1

  公开（公告）日：2008-06-26

  Esters of 2-phenylalkanenitriles, such as 3-acetoxy-2-(2-chloro-5-(difluoromethoxy)phenyl)propanenitrile and 3-acetoxy-2-(4-chlorophenyl)propanenitrile, and compositions containing such esters, are useful as fungicides at very low concentrations.

  2-苯基烷基腈的酯，如3-乙氧基-2-(2-氯-5-(二氟甲氧基)苯基)丙腈和3-乙氧基-2-(4-氯苯基)丙腈，以及含有这些酯的组合物，在极低浓度下作为杀真菌剂是有用的。
• 1-H-3-aryl-pyrrolidine-2, 4-dione derivatives as pest-control agents
  申请人：Bayer Aktiengesellschaft

  公开号：US06472419B1

  公开（公告）日：2002-10-29

  The present invention relates to new 1-H-3-aryl-pyrrolidine-2,4-dione derivatives of the formula (I) in which A, B, G, X, Y and Z have the meanings given in the description, to processes for their preparation, and to intermediates therefor. The compounds of the formula (I) are used as pesticides.

  本发明涉及新的式(I)的1-H-3-芳基吡咯烷-2,4-二酮衍生物，其中A、B、G、X、Y和Z的含义如描述中所述，以及其制备过程和中间体。式(I)的化合物被用作杀虫剂。
• [EN] SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES<br/>[FR] PYRROLIDINE-2-CARBOXAMIDES SUBSTITUÉS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2010031713A1

  公开（公告）日：2010-03-25

  There are provided compounds of the formula (I) wherein X, Y, R1, R2, R3, R3, R4, R5, R6 and R7 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

  提供了公式（I）的化合物，其中X，Y，R1，R2，R3，R3，R4，R5，R6和R7如本文所述，并提供其对映体和药学上可接受的盐和酯。这些化合物可用作抗癌剂。